Nirmatrelvir clinical trials
Also written PF-07321332.
Counted the way a researcher would: Nirmatrelvir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses nirmatrelvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nirmatrelvir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 May 2023 · PAXLOVID (COPACKAGED) · NDA 217188 (FDA, Drugs@FDA; in a combination)
- European Union
- 28 Jan 2022 · Paxlovid · EMEA/H/C/005973 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2022 (13)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 12 |
| 2022 | 13 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 5
Pfizer (22) · University of Melbourne (1) · Stanford University (1) · Harlan M Krumholz (1) · Genuine Research Center, Egypt (1) · UMC Utrecht (1) · University of Oxford (1)
Often tested with
Tested in the same studies.
Ritonavir (11) · Remdesivir (3) · Hydroxychloroquine (2) · Ivermectin (2) · Nirmatrelvir and ritonavir drug combination (2) · Nafamostat (1) · Enoxaparin (1) · Dalteparin (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nirmatrelvir.
- Jan 2027Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Phase 2 · University of Oxford
Studies
Open first, then newest update. How each study uses nirmatrelvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Nirmatrelvir/ritonavir + remdesivirHow we know
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)How we know
- EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseaseRecruitingPhase 3PfizerNCT05261139Written as nirmatrelvirHow we know
- A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19TerminatedPhase 1PfizerNCT05386472Written as nirmatrelvirHow we know
- A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating WomenCompletedPhase 1PfizerNCT05441215Written as nirmatrelvirHow we know
- Paxlovid for Treatment of Long CovidCompletedPhase 2Stanford UniversityNCT05576662Written as NirmatrelvirHow we know
- EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19CompletedPhase 2/3PfizerNCT04960202Written as PF-07321332How we know
- Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet FormulationCompletedPhase 1PfizerNCT05263895Written as PF-07321332/ritonavirHow we know
- A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.CompletedPhase 2Harlan M KrumholzNCT05668091Written as NirmatrelvirHow we know
- STUDY OF PF-07321332 IN HEALTHY PARTICIPANTSCompletedPhase 1PfizerNCT04756531Written as PF-07321332 Dose 1How we know
- A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.CompletedPhase 1PfizerNCT05339334Written as PF-07321332/ritonavirHow we know
- A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/RitonavirCompletedPhase 2PfizerNCT05567952Written as nirmatrelvirHow we know
- A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune SystemCompletedPhase 2PfizerNCT05438602Written as NirmatrelvirHow we know
- A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney DiseaseTerminatedPhase 1PfizerNCT05487040Written as PF-07321332 (nirmatrelvir)/ritonavirHow we know
- Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy ParticipantsCompletedPhase 1PfizerNCT05263921Written as PF-07321332/ritonavirHow we know
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialActive, not recruitingPhase 3University of MelbourneNCT04483960Written as Nirmatrelvir-RitonavirHow we know
- PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy ParticipantsCompletedPhase 1PfizerNCT05064800Written as PF-07321332/ritonavir + DabigatranHow we know
- Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With RitonavirCompletedPhase 1PfizerNCT04962230Written as PF-07321332/ritonavirHow we know
- Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult ParticipantsCompletedPhase 1PfizerNCT05129475Written as PF-07321332/ritonavirHow we know
- Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy ParticipantsCompletedPhase 1PfizerNCT05032950Written as PF-07321332/ritonavir + MidazolamHow we know
See all 28 studies that test nirmatrelvir →
As the comparator · 1 — what is tested is compared with nirmatrelvir
Codes
What other systems call nirmatrelvir · ClinicalTrials.gg INT001662
- MeSH (NLM) C000718217nirmatrelvirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7R9A5P7H32NIRMATRELVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2587892One source FDA
- Wikidata Q106405348nirmatrelvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C182119NirmatrelvirOne source FDA
- DrugBank DB16691One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718217 | nirmatrelvir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7R9A5P7H32 | NIRMATRELVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2587892 | — | One source FDA |
| Wikidata | Q106405348 | nirmatrelvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C182119 | Nirmatrelvir | One source FDA |
| DrugBank | DB16691 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.